Table 5.
Impact of pH modulation on antitumor activity in IMR-32 neuroblastoma xenografts
| Treatment | Median survival (days) |
95% Lower confidence limit |
95% Upper confidence limit |
Log rank statistic |
P value |
|---|---|---|---|---|---|
| Control | 9.0 ± 0.7 | 7.6 | 10.4 | ||
| MIBG/Glu | 10.0 ± 0.8 | 8.4 | 11.6 | 1.727 | 0.189 |
| CPT-11 | 8.0 ± 2.4 | 3.3 | 12.7 | 0.313 | 0.576 |
| BACPTDP | 11.0 ± 0.4 | 10.2 | 11.8 | 3.346 | 0.067 |
| CPT-11 + MIBG/Glu | 11.0 ± 1.5 | 8.1 | 13.9 | 5.023 | 0.025 |
| BACPTDP + MIBG/Glu | 14.0 ± 4.0 | 6.1 | 21.9 | 9.743 | 0.002 |
Groups of 10 Balb/C nude mice bearing 150 mm3 subcutaneous xenografts of IMR32 neuroblastoma tumor were treated intraperitoneally on days 1–5 with BACPTDP (5 mg/kg) or irinotecan (40 mg/kg), or pretreated with MIBG (32 mg/kg) plus glucose (1.5 g/kg) 30 min prior to administration of BACPTDP or irinotecan. Survival was measured as time to reach three tumor volume doublings (computed as L × W2/2), followed by Kaplan–Meier survival analysis with log rank test for significance